CRVONasdaqPharmaceutical PreparationsFiscal year ends December 31
CervoMed Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026
$2.31+0.07 (+3.12%)
Close on Oct 19, 2026
- Market cap
- $23.66M
- P/E (TTM)
- –
- Dividend yield
- –
CervoMed Inc. revenue by segment
By business segment
| Revenue | FY2013 | FY2012 | % of revenue | YoY |
|---|---|---|---|---|
| ProElite | $72 | $375 | 0.1% | -80.8% |
| Total | $72 | $375 | 0.1% | -80.8% |
| Other [Member] | $0 | $0 | 0.0% | – |
| Stratus Rewards [Member] | $0 | $0 | 0.0% | – |
| Other Events [Member] | $0 | $0 | 0.0% | – |
| Operating income | FY2013 | FY2012 | YoY |
|---|---|---|---|
| ProElite | $70 | $137 | -48.9% |
| Stratus Rewards [Member] | $0 | $0 | – |
| Other Events [Member] | -$87 | $0 | – |
| Other [Member] | -$587 | -$32 | +1734.4% |
| Total | -$604 | $105 | -675.2% |
By product or service
By region
From the segment and revenue-disaggregation notes of CervoMed's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.